ЛАФЕРОБИОН® (interferon alpha 2b recombinant)

General characteristics. Structure:

Active ingredients: interferon alpha 2b recombinant 150 000 ME, either 500 000 ME, or  1 000 000 ME, or  3 000 000 ME;

excipients: tocopherol acetate, ascorbic acid, solid fat.

Main properties: suppositories of a bullet form, yellow-white color, homogeneous consistence.

Pharmacological properties:

Interferon alpha 2b recombinant possesses the expressed anti-virus, anti-proliferative and immunomodulatory action. The complex structure ^{of Laferobiona®} causes a number of new effects: in combination with tocopherol acetate and ascorbic acid anti-virus activity of interferon alpha 2b recombinant increases at 10-14 times, its immunomodulatory action on T amplifies - and V-lymphocytes, the content of immunoglobulin E is normalized. The antibodies neutralizing anti-virus activity of interferon alpha 2b recombinant even at its use on an extent of 2 years are not formed, functioning of endogenous system is normalized.

Indications to use:

At adults:

- at papilomovirusny infections (vulgar warts, sharp-pointed to a condyloma);

- at urogenital a mix infections which are transferred sexually;

- at bacterial, virus and multi-infections;

- at pretumor diseases of a neck of uterus;

At children:

In complex therapy different infectious and inflammatory diseases at children, including, newborn and premature:

- at the acute respiratory viral infections (ARVI), pneumonia (bacterial, virus, Chlamidia), meningitis, sepsis, a specific pre-natal infection (clamidiosis, herpes, a cytomegaly, an enteroviral infection, visceral candidiasis, mycoplasmosis);

- for treatment Epstein-Barre of a viral infection at children.

Route of administration and doses:

At adults:

- at a papilomovirusny infection drug is appointed on  1 500 000 ME 2 times a day with a 12-one-hour break rektalno. Course of treatment of 10 days. Treatment is carried out under control of a cytologic, bacteriological research and manifestations of clinical symptoms;

- at urogenital the mix infections which are transferred sexually and at bacterial virus and multi-infections drug is appointed on    1 000 000 – 1 500 000 ME by 2 times a day with a 12-one-hour break rektalno. Course of treatment of 10 days. Treatment is carried out under control of a cytologic, bacteriological research and manifestations of clinical symptoms. Treatment is carried out both to sexual partners;

- at pretumor diseases of a neck of uterus: on  1 500 000 ME 2 times a day with a 12-chaosvy break rektalno. Course of treatment of 10 days. Further treatment is defined by clinical laboratory indicators.

At children:

- in complex therapy of different infectious and inflammatory diseases at children, including newborn and premature, drug is appointed on 150 000 ME on 2 suppositories a day with a 12-hour interval rektalno. Courses of treatment and intervals between courses – for 5 days.

It is recommended quantities of courses:

at a SARS – 1, pneumonia (bacterial – 1-2, virus – 1, Chlamidia – 1), meningitis – 1-2, sepsis – 2-3, at specific pre-natal infections (herpetic – 2, Cytomegaloviral – 2-3, enteroviral – 1-2, mycoplasmosis – 2-3).

To premature novorodzhenny children with gestational age less than 34 weeks 3 times a day (in 8 hours) rektalno appoint drug on 150 000 ME (1 suppository). The course makes 5 days.

- at леченииі Epstein-Barre of a viral infection at children drug is appointed at the rate of 1 million ME to 1 ^sq.m of the area of a body a day rektalno.

Drug is accepted by 2 times a day with an interval of 12 hours. The course of treatment sostalyat 10 days.

Features of use:

Treatment ^{of Laferobionom®} should be carried out under observation of the doctor.

At prolonged use of drug carry out control of the general blood test, functions of a liver, kidneys and a thyroid gland.

After the termination of a period of validity use of drug is inadmissible. Drug is not subject to requality control and extension of a period of validity after its termination.

Side effects:

All side reactions connected  using ^{Laferobiona®} insignificant or moderately severe. After the end of treatment they, usually disappear.

At introduction ^{of Laferobiona®} gripopodobny symptoms are possible: fever, temperature increase, fatigue, slackness, and also headache, muscle, joints pain, perspiration. For weakening of grippopodobny symptoms purpose of paracetamol is recommended.

From system of a hemopoiesis: at prolonged use the leukopenia, thrombocytopenia, anemia are possible.

From a GIT, liver: increase in the ALT and nuclear Heating Plant level, increase in the ShchF level.

From TsNS: at prolonged use  dizziness, a sleep disorder are possible.

From cardiovascular system: perhaps arterial hypertension or hypotension; seldom – tachycardia.

Allergic reactions.

Contraindications:

- hypersensitivity to recombinant interferon alfa-2 to b or other component of drug;

- diseases of a thyroid gland;

- heavy disturbances of functions of kidneys, liver;

- serious cardiovascular illness;

- epilepsy and other diseases of TsNS (including functional);

- oppression of a myeloid sprout of a hemopoiesis.

Storage conditions:

In the place protected from light, at a temperature from 2 °C to 8 °C.

Issue conditions:

According to the recipe

Packaging:

On 3 mln units on 5 suppositories in planimetric cell-like packaging, on one planimetric cell-like packaging in a pack.